Trial site
Shikoku Cancer Center
Matsuyama, 791-0280, JapanNot linked to an institution yet
- 14running trials
- 5closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 22 trials
- Phase 11 trial
- Phase 1/21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting10 trials
- Completed5 trials
- Recruiting4 trials
- Lead sponsor
- Hoffmann-La Roche2 trials
- Incyte Corporation2 trials
- National Cancer Institute (NCI)2 trials
- Australasian Gastro-Intestinal Trials Group1 trial
- Genmab1 trial
- and 11 more
Running trials
Active, not recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07214779· Phase 3· Incyte Corporation· Source
Recruiting
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
NCT07023627· Phase 2· Incyte Corporation· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Active, not recruiting
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
NCT06390995· Phase 1/2· Takeda· Source
Recruiting
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
NCT06248411· Phase 1· Kyowa Kirin Co., Ltd.· Source
Contact: Kyowa Kirin Co., Ltd.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· Phase 3· NRG Oncology· Source
Contact: Daisuke Takabatake (principal investigator)
Active, not recruiting
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754· Phase 3· Servier Affaires Médicales· Source
Active, not recruiting
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147· Phase 3· Jazz Pharmaceuticals· Source
Active, not recruiting
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
NCT05043922· Phase 2· Haihe Biopharma Co., Ltd.· Source
Active, not recruiting
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
Phase III Trial of Stage I Ovarian Cancer After Surgery
NCT04063527· Phase 3· Japanese Gynecologic Oncology Group· Source
Contact: Kazuhiro Takehara
Active, not recruiting
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851· Phase 3· National Cancer Institute (NCI)· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error